ImmunoGen looks for $39M in stock offering

Massachusetts-based ImmunoGen is offering 5 million shares of its stock at a price of $7.00 per share. The company is hoping to raise a total of $33 million after underwriting discounts, commissions and expenses. The company has granted the underwriters a thirty day option to purchase up to an additional 750,000 shares to cover any over-allotments. Oppenheimer & Co is acting as the sole book-runner for the offering

Immunogen is developing anticancer therapeutics with its Targeted Antibody Payload (TAP) technology. The company recently landed a $6.5 million milestone payment form for its work on a breast cancer therapy program in development with Genentech. Immunogen is also collaborating with Sanofi-Aventis, Biogen Idec and Biotest on compounds utilizing TAP technology.

- here's ImmunoGen's announcement
- read the MassHighTech report

Suggested Articles

Less than two years after taking the reins from founding chief Rusty Williams, Five Prime Therapeutics CEO Aron Knickerbocker is exiting the company.

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…